Cubist Systematic Strategies’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-483,797
Closed -$9.87M 2910
2025
Q1
$9.6M Buy
483,797
+99,721
+26% +$1.72M 0.06% 497
2024
Q4
$6.59M Buy
+384,076
New +$7.23M 0.04% 674
2024
Q3
Sell
-463,685
Closed -$7.21M 2922
2024
Q2
$5.18M Sell
463,685
-567,758
-55% -$4.76M 0.04% 760
2024
Q1
$6.81M Buy
1,031,443
+800,512
+347% +$4.38M 0.04% 761
2023
Q4
$1.04M Sell
230,931
-69,833
-23% -$258K 0.01% 2030
2023
Q3
$1.08M Sell
300,764
-26,459
-8% -$102K 0.01% 1838
2023
Q2
$1.21M Buy
327,223
+186,440
+132% +$691K 0.01% 1845
2023
Q1
$466K Buy
140,783
+18,652
+15% +$64.5K ﹤0.01% 2708
2022
Q4
$474K Buy
+122,131
New +$377K ﹤0.01% 3061
2022
Q2
Sell
-317,542
Closed -$581K 4334
2022
Q1
$581K Buy
317,542
+129,742
+69% +$202K ﹤0.01% 2438
2021
Q4
$265K Buy
+187,800
New +$247K ﹤0.01% 2885
2021
Q3
Sell
-62,484
Closed -$100K 2931
2021
Q2
$100K Buy
62,484
+19,184
+44% +$33.8K ﹤0.01% 2714
2021
Q1
$76K Buy
+43,300
New +$99.1K ﹤0.01% 2688
2020
Q2
Sell
-6,096
Closed -$18K 2374
2020
Q1
$18K Buy
+6,096
New +$21.1K ﹤0.01% 2067

Other funds holding ADMA

Cubist Systematic Strategies's ADMA Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 483,797 shares — an estimated $9.87M sold.

Cubist Systematic Strategies first reported a position in ADMA in Q1 2020 and held it in 14 quarters. The position peaked at $9.6M in Q1 2025. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • Cubist Systematic Strategies reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 483,797 ADMA Biologics shares in Q2 2025, an estimated $9.87M.
  • Cubist Systematic Strategies first reported a position in ADMA Biologics in Q1 2020 and held it in 14 quarters.
  • Cubist Systematic Strategies's ADMA Biologics position peaked at $9.6M in Q1 2025.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.